J H E Yong1, T McGowan2, R Redmond-Misner1, J Beca1, P Warde3, E Gutierrez4, J S Hoch5. 1. St. Michael's Hospital, Toronto, ON;; Cancer Care Ontario, Toronto, ON;; Canadian Centre for Applied Research in Cancer Control, Toronto, ON; 2. Department of Radiation Oncology, Faculty of Medicine, University of Toronto, Toronto, ON;; The Cancer Centre Bahamas, Nassau, Bahamas;; The Cancer Centre Eastern Caribbean, St. John's, Antigua; 3. Canadian Centre for Applied Research in Cancer Control, Toronto, ON;; Department of Radiation Oncology, Faculty of Medicine, University of Toronto, Toronto, ON;; Princess Margaret Hospital, University of Toronto, Toronto, ON. 4. Cancer Care Ontario, Toronto, ON; 5. St. Michael's Hospital, Toronto, ON;; Cancer Care Ontario, Toronto, ON;; Canadian Centre for Applied Research in Cancer Control, Toronto, ON;; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON.
Abstract
BACKGROUND: Radiotherapy is a common treatment for many cancers, but up-to-date estimates of the costs of radiotherapy are lacking. In the present study, we estimated the unit costs of intensity-modulated radiotherapy (imrt) and 3-dimensional conformal radiotherapy (3D-crt) in Ontario. METHODS: An activity-based costing model was developed to estimate the costs of imrt and 3D-crt in prostate cancer. It included the costs of equipment, staff, and supporting infrastructure. The framework was subsequently adapted to estimate the costs of radiotherapy in breast cancer and head-and-neck cancer. We also tested various scenarios by varying the program maturity and the use of volumetric modulated arc therapy (vmat) alongside imrt. RESULTS: From the perspective of the health care system, treating prostate cancer with imrt and 3D-crt respectively cost $12,834 and $12,453 per patient. The cost of radiotherapy ranged from $5,270 to $14,155 and was sensitive to analytic perspective, radiation technique, and disease site. Cases of head-and-neck cancer were the most costly, being driven by treatment complexity and fractions per treatment. Although imrt was more costly than 3D-crt, its cost will likely decline over time as programs mature and vmat is incorporated. CONCLUSIONS: Our costing model can be modified to estimate the costs of 3D-crt and imrt for various disease sites and settings. The results demonstrate the important role of capital costs in studies of radiotherapy cost from a health system perspective, which our model can accommodate. In addition, our study established the need for future analyses of imrt cost to consider how vmat affects time consumption.
BACKGROUND: Radiotherapy is a common treatment for many cancers, but up-to-date estimates of the costs of radiotherapy are lacking. In the present study, we estimated the unit costs of intensity-modulated radiotherapy (imrt) and 3-dimensional conformal radiotherapy (3D-crt) in Ontario. METHODS: An activity-based costing model was developed to estimate the costs of imrt and 3D-crt in prostate cancer. It included the costs of equipment, staff, and supporting infrastructure. The framework was subsequently adapted to estimate the costs of radiotherapy in breast cancer and head-and-neck cancer. We also tested various scenarios by varying the program maturity and the use of volumetric modulated arc therapy (vmat) alongside imrt. RESULTS: From the perspective of the health care system, treating prostate cancer with imrt and 3D-crt respectively cost $12,834 and $12,453 per patient. The cost of radiotherapy ranged from $5,270 to $14,155 and was sensitive to analytic perspective, radiation technique, and disease site. Cases of head-and-neck cancer were the most costly, being driven by treatment complexity and fractions per treatment. Although imrt was more costly than 3D-crt, its cost will likely decline over time as programs mature and vmat is incorporated. CONCLUSIONS: Our costing model can be modified to estimate the costs of 3D-crt and imrt for various disease sites and settings. The results demonstrate the important role of capital costs in studies of radiotherapy cost from a health system perspective, which our model can accommodate. In addition, our study established the need for future analyses of imrt cost to consider how vmat affects time consumption.
Authors: Racquel E Kohler; Nathan C Sheets; Stephanie B Wheeler; Chris Nutting; Emma Hall; Bhishamjit S Chera Journal: Int J Radiat Oncol Biol Phys Date: 2013-11-15 Impact factor: 7.038
Authors: Florian Rudolf Schroeck; Bruce L Jacobs; Sam B Bhayani; Paul L Nguyen; David Penson; Jim Hu Journal: Eur Urol Date: 2017-03-31 Impact factor: 20.096
Authors: Andrea C Lo; Lyndon P James; Anca Prica; Adam Raymakers; Stuart Peacock; Melody Qu; Alex V Louie; Kerry J Savage; Laurie H Sehn; David Hodgson; Joanna C Yang; Hans T T Eich; Andrew Wirth; M G Myriam Hunink Journal: J Nucl Med Date: 2021-08-19 Impact factor: 10.057